June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Cost-utility analysis of screening program for diabetic retinopathy in Japan: a probabilistic Markov modeling study
Author Affiliations & Notes
  • Ryo Kawasaki
    Dept of Public Health/Dept of Ophthalmology, Yamagata University, Yamagata, Japan
  • Yoko Akune
    National Institute of Sensory Organs,, National Tokyo Med Center, Tokyo, Japan
  • Yoshimune Hiratsuka
    National Institute of Public Health, Saitama, Japan
  • Masakazu Yamada
    National Institute of Sensory Organs,, National Tokyo Med Center, Tokyo, Japan
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1546. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ryo Kawasaki, Yoko Akune, Yoshimune Hiratsuka, Masakazu Yamada; Cost-utility analysis of screening program for diabetic retinopathy in Japan: a probabilistic Markov modeling study. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1546.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the cost-effectiveness of screening program for diabetic retinopathy through the estimation of the incremental costs per Quality Adjusted Life Years (QALYs) gained using the best available clinical data and scenario in Japan.

Methods: We framed a Markov model with a probabilistic cohort analysis to calculate the incremental costs per QALY gained by implementing screening program for diabetic retinopathy in Japan. A one-year cycle length and a population size of 50000 with 50 years time horizon (age 40 to 90 years old) were applied. Best available clinical data were collected from publications and a model was designed with data on the course of diabetic retinopathy including diagnosis, treatment and visual outcomes. We then simulated uncertainties using univariate and probabilistic sensitivity analysis.

Results: In base-case analysis, screening program for diabetic retinopathy was associated with incremental costs of Japanese yen (JPY) 5147 (US$64.6) and incremental effectiveness of 0.0054 QALYs per one screened person. The incremental cost effectiveness ratio (ICER) was JPY 944,981 (US$11,857) per QALY. Although reduction of low vision was modest (-5%), our simulation demonstrated significant reduction in persons with blindness (-16%) by screening for diabetic retinopathy. Our sensitivity analysis demonstrated that the most cost-effective screening program for diabetic retinopathy in Japan was to start screening at age of 53 years old with less than 5 years interval up to 84 years old.

Conclusions: Screening program for diabetic retinopathy in Japan is cost-effective even allowing for the uncertainty of the known variability that exists in estimates of costs, utilities, and complications rate. Further studies are warranted to determine the most effective screening strategy for preventing blindness from diabetic retinopathy.

Keywords: 499 diabetic retinopathy • 754 visual acuity • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×